Indeed, the presence of a high number of TILs in patients with residual disease after neoadjuvant therapy was associated with worse DFS (167), probably due to an increase in Treg cells (168), indicating that immune-mediated resistance mechanisms need to be inhibited in BC patients to guarantee a good response to HER2-targeted therapy. The gene discussed is ERBB2; the disease is breast cancer.